ALEC Alector (ALEC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001653087
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
72
13F, latest reported quarter
What the filings say about ALEC
Insiders, 180 days
-$523.8K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$292.8K
5 notices
Alector insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Alector, Inc. insiders sold a net $523.8K of stock across 123 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Sep 3, 2026.
- The trade is 3.4% of the 106,015 shares held after it.
- 2 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Wong-Sarad Grace sold about $9.1K of ALEC on Sep 4, 2026; 2 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Sep 2, 2026.
- The trade is 4.7% of the 109,640 shares held after it.
- 2 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Wong-Sarad Grace sold about $13.8K of ALEC on Sep 3, 2026; 2 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 2, 2026.
- The trade is 8.3% of the 350,649 shares held after it.
- 2 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO & Chief Business Officer Berkley Neil Lindsay sold about $77.9K of ALEC on Sep 3, 2026; 2 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Jun 2, 2026.
- The trade is 3.2% of the 2,294,600 shares held after it.
- 2 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Rosenthal Arnon sold about $193.5K of ALEC on Sep 3, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jun 3, 2026.
- The trade is 0.6% of the 114,805 shares held after it.
- 2 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Wong-Sarad Grace sold about $1.8K of ALEC on Sep 2, 2026; 2 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.123 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$523.8K over 180 days
-$296.1K over 90 days
below 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
72 funds bought in last quarter
more than 57% of Pharma & Biotech
Revenue
-79.1% year over year
below 87% of Pharma & Biotech
Margin
-679.2% net margin
below 81% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.5% of the float short (float per yahoo 2026-10-26) · 5.7 days to cover · settled 2026-09-30
more than 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ALEC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ALEC: institutional holders (13F)
13F holdings, latest reported quarter
10,000,000 sh
$20.1M
8,636,218 sh
$17.4M
7,847,879 sh
$15.8M
4,009,340 sh
$8.1M
3,808,494 sh
$7.7M
Congress trades in ALEC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ALEC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
GRACE WONG-SARAD
Filed 2026-09-04
$9.1K
GRACE WONG-SARAD
Filed 2026-09-02
$1.8K
Neil L. Berkley
Filed 2026-09-01
$77.0K
Arnon Rosenthal
Filed 2026-09-01
$191.3K
Grace Wong-Sarad
Filed 2026-09-01
$13.6K
ALEC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$68.3K position · as of 2026-05-31
0.4%
Ultra-Small Company Market Fund
$286.4K position · as of 2026-06-30
0.2%
NVIT Small Cap Value Fund
$268.1K position · as of 2026-06-30
0.1%
SMALL COMPANY GROWTH PORTFOLIO
$1.2M position · as of 2026-06-30
0.1%
NVIT Multi-Manager Small Company Fund
$300.5K position · as of 2026-06-30
0.1%
Select Biotechnology Portfolio
$3.0M position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 2
0 active
2
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.0M
$1.9M
$1.3M
-83%
+35%
2024
$3.7M
-$1.8M
$1.9M
-80%
+2%
2023
$4.3M
$3.2M
$2.0M
-14%
+4%
2022
$3.5M
-$7.8M
$3.9M
-46%
+11%
2021
$9.6M
$15.2M
$1.4M
+20%
+25%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $523.8K sold by insiders over 180 days, 72 funds added last quarter, $292.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ALEC financials
Revenue growth
-79.1%
XBRL, annual
Net margin
-679.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$13.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ALEC
| FY Dec 2025 | $21.1M |
| FY Dec 2024 | $100.6M |
| FY Dec 2023 | $97.1M |
| FY Dec 2022 | $133.6M |
| FY Dec 2021 | $207.1M |
| Jun 2026 | $3.3M |
| Mar 2026 | $1.0M |
| Dec 2025 | $6.2M |
| Sep 2025 | $3.3M |
| Jun 2025 | $7.9M |
| Mar 2025 | $3.7M |
| Dec 2024 | $54.3M |
| Sep 2024 | $15.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-850.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ALEC
| FY Dec 2025 | -678.7% |
| FY Dec 2024 | -118.3% |
| FY Dec 2023 | -133.9% |
| FY Dec 2022 | -99.8% |
| FY Dec 2021 | -17.5% |
| Jun 2026 | -692.5% |
| Mar 2026 | -2,192% |
| Dec 2025 | -598.7% |
| Sep 2025 | -1,063% |
| Jun 2025 | -387.7% |
| Mar 2025 | -1,094% |
| Dec 2024 | -3.7% |
| Sep 2024 | -275.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$158.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ALEC
| FY Dec 2025 | -$184.1M |
| FY Dec 2024 | -$231.2M |
| FY Dec 2023 | -$186.5M |
| FY Dec 2022 | -$24.4M |
| FY Dec 2021 | $295.3M |
| Jun 2026 | -$34.2M |
| Mar 2026 | -$49.9M |
| Dec 2025 | -$41.7M |
| Sep 2025 | -$32.5M |
| Jun 2025 | -$49.1M |
| Mar 2025 | -$60.8M |
| Dec 2024 | -$55.2M |
| Sep 2024 | -$50.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity ALEC
| FY Dec 2025 | 0.32x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | 0.94x |
| Dec 2025 | 0.32x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.13x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-16.07x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ALEC
| FY Dec 2025 | -18.99x |
| FY Dec 2024 | -24.49x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -16.07x |
| Mar 2026 | -17.72x |
| Dec 2025 | -18.99x |
| Sep 2025 | -20.54x |
| Jun 2025 | -22.61x |
| Mar 2025 | -24.23x |
| Dec 2024 | -24.49x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-385.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ALEC
| FY Dec 2025 | -181.6% |
| FY Dec 2024 | -91.2% |
| FY Dec 2023 | -74.6% |
| FY Dec 2022 | -51.8% |
| FY Dec 2021 | -12.8% |
| Jun 2026 | -385.3% |
| Mar 2026 | -239.0% |
| Dec 2025 | -181.6% |
| Sep 2025 | -121.9% |
| Jun 2025 | -103.9% |
| Mar 2025 | -90.2% |
| Dec 2024 | -91.2% |
| Sep 2024 | -112.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-42.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ALEC
| FY Dec 2025 | -37.6% |
| FY Dec 2024 | -21.8% |
| FY Dec 2023 | -18.4% |
| FY Dec 2022 | -16.6% |
| FY Dec 2021 | -5.6% |
| Jun 2026 | -42.2% |
| Mar 2026 | -38.7% |
| Dec 2025 | -37.6% |
| Sep 2025 | -25.3% |
| Jun 2025 | -24.9% |
| Mar 2025 | -23.6% |
| Dec 2024 | -21.8% |
| Sep 2024 | -26.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ALEC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-57.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ALEC
| FY Dec 2025 | -55.0% |
| FY Dec 2024 | -36.8% |
| FY Dec 2023 | -26.7% |
| FY Dec 2022 | -20.1% |
| FY Dec 2021 | -6.8% |
| Jun 2026 | -57.4% |
| Mar 2026 | -54.8% |
| Dec 2025 | -55.0% |
| Sep 2025 | -39.3% |
| Jun 2025 | -38.7% |
| Mar 2025 | -38.0% |
| Dec 2024 | -36.8% |
| Sep 2024 | -41.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ALEC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$154.3M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ALEC
| FY Dec 2025 | $114.2M |
| FY Dec 2024 | $161.5M |
| FY Dec 2023 | $596.9M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $173.1M |
| Mar 2026 | $170.1M |
| Dec 2025 | $114.2M |
| Sep 2025 | $232.7M |
| Jun 2025 | $104.8M |
| Mar 2025 | $93.4M |
| Dec 2024 | $161.5M |
| Sep 2024 | $416.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-77.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield ALEC
| FY Dec 2025 | -108.1% |
| FY Dec 2024 | -124.9% |
| FY Dec 2023 | -27.8% |
| FY Dec 2022 | -3.2% |
| FY Dec 2021 | +17.6% |
| Jun 2026 | -71.0% |
| Mar 2026 | -73.0% |
| Dec 2025 | -108.1% |
| Sep 2025 | -66.0% |
| Jun 2025 | -154.3% |
| Mar 2025 | -188.8% |
| Dec 2024 | -124.9% |
| Sep 2024 | -49.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ALEC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $21.0M | $100.6M | $97.1M | $133.6M |
| Operating income | -$156.0M | -$145.0M | -$151.7M | -$137.8M |
| Net income | -$143.0M | -$119.0M | -$130.0M | -$133.3M |
| EPS (diluted) | -1.39 | -1.23 | -1.56 | -1.62 |
| Operating cash flow | -$184.0M | -$229.9M | -$184.2M | -$20.3M |
| Cash | $65.8M | $33.0M | $74.6M | $154.3M |
| Long-term debt | $9.3M | $9.4M | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
ALEC Stock Sonar score 6/7 axes
Find similar shapesCompareALEC ranks highest on institutional and government (57th percentile) and risk and compliance (44th), and lowest on growth (13th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ALEC filings, in plain words
Are Alector insiders buying or selling ALEC?
In the 180 days to 2026-10-27, Alector insiders were net sellers, a net $523.8K across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of ALEC?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $292.8K of stock; the latest, by GRACE WONG-SARAD, was filed 2026-09-04.
Read the full summary
In the 180 days to 2026-10-27, Alector insiders were net sellers of ALEC, a net $523.8K across purchases and sales reported on Form 4 by 3 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $292.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
